Selecta Biosciences (NASDAQ:SELB) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Selecta Biosciences (NASDAQ:SELB) posted its earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.07), Bloomberg Earnings reports. The firm had revenue of $0.01 million for the quarter.

NASDAQ:SELB traded up $0.02 during mid-day trading on Friday, reaching $1.80. 123,216 shares of the company were exchanged, compared to its average volume of 195,848. Selecta Biosciences has a 12 month low of $1.41 and a 12 month high of $16.55. The firm’s fifty day moving average is $1.78. The stock has a market capitalization of $85.99 million, a PE ratio of -0.62 and a beta of 1.17.

Several equities research analysts have recently weighed in on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $6.00 target price on shares of Selecta Biosciences in a report on Friday. ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research lowered shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, July 11th. Finally, Mizuho reaffirmed a “buy” rating and issued a $4.00 target price on shares of Selecta Biosciences in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $7.88.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.

See Also: Why do analysts give a neutral rating?

Earnings History for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.